MannKind (MNKD) delivered strong financial results for the fourth quarter — noteworthy for the best-ever quarterly sales of the inhaled insulin Afrezza and the product’s first-ever gross profit.
This is news largely because the words “MannKind” and “strong financial results” have never appeared together in a sentence. In almost all respects, MannKind has been a raging, insulin-delivery dumpster fire, so give management credit for a quarter that hints at a turnaround. There’s still a long way to go.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
